Our Technology

EptivA Therapeutics has developed the first precision medicine approach to pain to create more effective treatments and increase clinical success.

a receptor target.png

Current R&D still relies on non-translatable preclinical models with a focus on a single node of data, the target receptor

Our innovative new approach

Eptiva logo.png
a knowledge map_edited.jpg

We have created a Personalized Analgesics® bioinformatic approach which creates 1000’s nodes of data via novel human-focused network biology linked to our proprietary Pain Landscape®

EptivA Therapeutics Ltd has a patent pending for research and methods relating to Personalized Analgesics® research 

A case study: EPT-101

EPT-101 represents a novel, non-opioid analgesic for specific pain conditions identified via our technology

A PA example labels.png

Using the Personalized Analgesics® research platform we have identified a previously unknown local application for EPT-101 in pain, particularly forms of neuropathic pain.

 

Our research shows that EPT-101 modulates mechanisms which reduce the keratin  sensitization, immuno-inflammation and neuronal hyperexcitibility which drives pain in specific neuropathy conditions.

Our data has being used to create new IP to protect EPT-101 for its use in pain.